Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kemira Annual Report 2021 published

Kemira Oyj, Annual Financial Report, February 18, 2022 at 12 pm (EET)Kemira Annual Report 2021 published Kemira’s Annual Report 2021 has been published in PDF format in English at www.kemira.com > Investors > Reports and presentations  on February 18, 2022 at 12 pm (EET). The publication consists of the following modules: Annual Review, Sustainability Report, Corporate Governance Statement and Financial Statements. The Financial Statements and Corporate Governance Statement are available in both English and Finnish,

CS MEDICA A/S: Publication of interim report Q1

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby publishes its interim report for the period October 2021 – December 2021. The report is available as an attached document to this press release and on the Company’s website (www.cs-medica.com). Below is a summary of the report.Performance highlights – First quarter (October 2021 – December 2021) · In line with our previous expectations, our first quarter revenue, tDKK 127, is lower than the corresponding quarter in 2020/2021, tDKK 685, where revenue was generated through insale to the shelf of Matas 186 medicare shops.  In this post

Climate-neutral bus transport in Frankfurt am Main with green hydrogen

Herning, Denmark, 18 February 2022 – In-der-City-Bus GmbH orders heavy-duty hydrogen station from Everfuel. In December 2021 it was announced that Everfuel had been awarded a contract by a public organisation in the Frankfurt area in Germany, and all parties have now signed the final contract. In a Europe-wide tendering procedure, In-der-City-Bus GmbH (ICB) has awarded Everfuel GmbH the contract for the planning, construction and commissioning of a hydrogen refuelling station. The contract also includes maintenance and servicing. Additionally, Everfuel was awarded the contract for the

Terveystalo’s Annual Report 2021 published

Terveystalo Plc Annual Financial Report 18 February 2022 at 11:30 am EET Terveystalo Plc has today published its Annual Report for the year 2021. The Annual Report 2021 consists of four parts: · Year 2021 presents the strategic development and key events that took place during the year. · Responsibility describes Terveystalo’s corporate responsibility efforts and their results in line with the GRI Standards Core reporting guidelines. · Corporate Governance includes the Corporate Governance Statement, Remuneration Policy and the Remuneration Report. · Financials includes

Company Announcement no. 20, 2022 – Nordea Kredit Realkreditaktieselskab drawings as per 1 April 2022

Nordea Kredit hereby announces drawings data for callable covered mortgage bonds (SDRO) as per 1 April 2022. The figures are published in order to comply with publication requirements in the transparency regulation 2017/1129/EU and the Danish Act on Capital Markets section 24.   Questions can be directed to Torben Jurlander phone +45 55 47 41 99.     Yours faithfully   Nordea Kredit Realkreditaktieselskab

Veg of Lund chooses NTEX for tailor-made logistics solutions

Veg of Lund has today signed an agreement with the Swedish logistics and transports company NTEX for warehouse and transport management. The aim is to jointly develop efficient and sustainable transport solutions, primarily within Europe, to meet Veg of Lund’s growing transport needs.Veg of Lund’s plant-based drink DUG[®] was launched in May 2021 and as volumes have grown, the company’s need for an efficient logistics partner has increased. The new agreement creates the conditions for a flexible solution that can be quickly adapted to the needs of both Veg of Lund and the company’s

Invitation to presentation of Pagero Group’s year-end report 2021

Pagero Group AB (publ) publishes year-end report for January – December 2021 on 25 February 2022 at 07.30 CET and invites to a presentation of the report at 10.00 CET on the same day.Bengt Nilsson, CEO of Pagero, will present Pagero’s fourth quarter in a webcast. It will be possible to submit questions in writing during the presentation, which will be answered at the end of the broadcast. Follow the presentation live: Link  For more informationBengt Nilsson, CEOBengt.nilsson@pagero.com Jan-Olof

Updated financial calendar

Holmen's financial calendar has been updated as the publication of interim reports and year-end report for 2022 is postponed by one day compared to what has previously been communicated.The financial reports for 2022 will be published in the morning and will be followed by a webcast press and analyst conference. Financial reporting 2022Interim report January – March: 28 April 2022Interim report January – June: 19 August 2022Interim report January – September: 20 October 2022Year-end report 2022: 31 January 2023 Holmen also invites analysts, investors and financial media to an

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 44 - 18 FEBRUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

JS Security's founder, board members and shareholders extend their lockup agreements

JS Security Technologies Group AB ("JS Security" or "the Company") announces today that the Company's founder Christopher Ramstedt, acting CEO Pontus Wilgodt, board member Per Holmstedt and another major shareholder will extend their lockup agreements. The extension includes a total of 1,418,320 shares. The extension takes effect at the same time as the existing agreements expire.The extension of the lockup agreements that have been signed today includes 1,418,320 shares, corresponding to 22.39% of the total number of shares. Christopher Ramstedt and Pontus Wilgodt extend their agreements

NCC to construct 87 tenant-owner apartments in central Skellefteå

NCC and HSB will initiate a partnering project and construct two buildings with 87 apartments in the growing city of Skellefteå. The order value is approximately SEK 190 million. NCC will continue the development of Skellefteå in cooperation with HSB and will construct two apartment blocks with five and twelve floors, respectively, containing 87 tenant-owner apartments in central Skellefteå. “The HSB Brf Guldläge project was very much appreciated by HSB’s home-savers and members. The beautiful buildings will add toward creating an even more attractive Skellefteå. Production

Amendment to the SEK subscription price of Loudspring´s rights issue

Loudspring OyjCompany release, inside information18 February 2022, 10:15(EET) Loudspring amends the SEK subscription price of its rights issue (released on February 17th 2022) according to instructions received from Euroclear Sweden.  The subscription price per Offer Share in Sweden has been modified to include only two decimals according to instructions received from Euroclear Sweden. The new subscription price per offer share in Sweden is SEK 1,09 (previously SEK 1,096). The subscription price per Offer Share in Finland has not been modified. The amended terms and conditions

BioStock: DexTech Medical’s CEO on the company’s platform technology

DexTech Medical develops drug candidates in oncology that are based on the CDC platform GuaDex, where different substances are combined with the carbohydrate molecule dextran. The company will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer. BioStock contacted DexTech’s CEO Anders R Holmberg to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2022/02/dextech-medicals-ceo-on-the-companys-platform-technology/ This

Getinge’s new modular room system helps hospitals create safe and functional workplaces

Getinge is today launching the new and extended modular room system Getinge IN2 – an intelligent solution for creating interconnected, sustainable and efficient workplaces in hospital departments around the world.“Getinge IN2, the successor to our Variop and Variward systems, is designed intuitively to evolve with cutting-edge technologies in the Operating Room (OR), Intensive Care Unit (ICU) and Central Sterile Supply Departments (CSSD). It complements nicely our existing range of equipment to provide complete, integrated turnkey solutions,” says Philippe Rocher, President at Getinge South

Nexam is recruiting for continued rapid expansion in wind power Hires Dane Momcilovic as responsible for PET applications

Nasdaq First North-listed Nexam Chemical has recruited Dane Momcilovic as Business Manager for the growing PET foam business area. Dane Momcilovic comes most recently from Polygiene and has previously been development manager at Diab. The assignment involves being responsible for further developing the PET foam business and expanding it with more products and customers. Dane Momcilovic will take up the post on March 1.Nexam Chemical helps plastics manufacturers around the world to improve their products - both in terms of durability and function - and thus competitiveness. Dane

Sanolium Interim report 4/2021

Revenues in the fourth quarter amounted to 196.6 MSEK, representing growth of 17.6%Support and maintenance fees constitute the largest share of the revenue. License revenues and Professional Services revenues are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the fourth quarter amounted to 28.3 (12.2) MSEK resulting in an adjusted EBITDA margin of 14.4 (7.3) %. Employee related expenses amounted to 136.3 (129.3) MSEK, representing an increase of 5.4%. The number of full-time employees rose to 747 in the fourth quarter, an

Year-end report January - December 2021 S2Medical AB (publ)

SUMMARY OF THE INTERIM REPORT During the fourth quarter, sales in regular wound healing products amounted to MSEK 1.4 (0.1) and increased on a full-year basis by 261% compared with 2020. The Group's Net sales during the quarter amounted to MSEK 1.6 (4.9). Net sales throughout the year amounted to MSEK 7.7 (25.6). During the fourth quarter of the previous year, the Company had increased turnover as a result of sales of medical consumables with the aim of preventing the spread of COVID-19. DEVELOPMENT WITHIN THE GROUP, OCTOBER – DECEMBER 2021 · Net sales within the Company's

AddSecure takes home a bronze medal in the Swedish Championships in Employer Branding

Fast-growing IoT company, AddSecure, received an award for its initiative "One company, one culture" during the Magnet Awards yesterday, a competition for Sweden's best and most efficient in employer communication.Magnet Awards  is a non-profit project that annually organizes the Swedish Championships in Employer Branding, a competition that pays tribute to employers who make a difference. The competition, which is the largest of its kind, highlights the best companies in Sweden in terms of employer communication. AddSecure  was awarded

Read original

The Nomination Committee's proposal for the election of Board members

The Nomination Committee of Micro Systemation AB, which consists of Erik Ivarsson (appointed by  AB Grenspecialisten) David Zaudy (appointed by Cervantes Capital) and Christian Hellman (appointed by Edastra AB), has decided to submit the following proposals to the 2022 Annual General Meeting regarding the number of Board members and the election of Board members. The Nomination Committee proposes that the number of Board members on the Board be reduced by one person and thus amount to five members. The Nomination Committee proposes the re-election as Board members of Bernt Ingman,

Invitation to Cereno Scientific webcast: Clinical Phase II study with drug candidate CS1 in PAH

Cereno Scientific (XSAT: CRNO B) invites investors, financial analysts, and media to a webcast presentation on February 25, 2022. The presentation will focus on the Phase II study of drug candidate CS1 in the rare disease pulmonary arterial hypertension (PAH). Chief Executive Officer, Sten R. Sörensen and Chief Medical Officer Dr. Björn Dahlöf from Cereno will be joined by Dr. Raymond Benza, Principal Investigator for the study and Dr. Philip Adamson, Vice President and Chief Medical Officer at study collaborator Abbott.  The presentations will cover the background, design, and plan for the

SAPA Series with Emma Ridderstad

It was not so long ago that parallel worlds were merely the staple of science fiction writers. Today however, the nascent technology of virtual and augmented reality is for the first time making it possible to talk about the merging of the digital and physical into a single, hybrid universe. Propelled by the booming gaming sector, virtual reality has in the last few years started to spill over into industries ranging from education and human resources, to construction and design. And yet, more than half a century after the very first VR headset was created in the US for military

DSRT: Desert Control H2 2021 Report and interim Financial Results | Webcast presentation 25 February 10:00 CET

ISSUER DESERT CONTROL AS Desert Control H2 2021 Report and Financial Results will be released on Friday25 February 2021 at 0800 AM Central European Time (Oslo).Report and presentation will be available at www.desertcontrol.comWebcast presentation in English will be hosted on Friday 25 February at 10.00 AMCentral European Time.Registration:https://desertcontrol.zoom.us/webinar/register/7816451668620/WN_gNoNVqAgSH6UrdqhZbkjwwAfter the presentation, there will be a moderated question and answers session.Questions for Q&A can be submitted in advance toerling.rasmussen@

Scandinavian ChemoTech’s subsidiary signs its first commercial contract for the US veterinary market

ChemoTech’s Animal Care division Vetiqure AB signs a contract with FloridaWild Veterinary Hospital (“FloridaWild”) in Deland, Florida as a direct result of a successful trade show in Orlando, which generated many leads.The contract with FloridaWild includes access to our vetIQure™ TSE device during an initial evaluation period and a commercial purchase of our treatment kits. In addition to the purchase of the treatment kits an order for the device will be placed following a successful evaluation. The joint goal with the agreement is to establish a Centre of Excellence with FloridaWild where

There are no items matching the current filter
There are no more items matching the current filter
Back to top